Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biktarvy vs Symtuza for Rapid Start in New HIV
NCT04653194Phase 3Completed
- Sponsor
- Chelsea and Westminster Hospital NHS Foundation Trust
- Start
- Sep 2020
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of bictegravir + emtricitabine + tenofovir alafenamide in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Chelsea and Westminster Hospital NHS Foundation Trust. Started Sep 2020; status: completed.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT04653194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04653194.